Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026
Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026
Same author

Demographic and Clinical Characteristics of Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Related Experiment Video

Updated: Apr 11, 2026

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.7K

Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Carolina A Rush1, Heather J MacLean1, Mark S Freedman1

  • 1Division of Neurology, Ottawa Hospital Multiple Sclerosis Research Unit, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

Nature Reviews. Neurology
|June 3, 2015
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a central nervous system disorder causing neurological disability. Identifying aggressive MS early is crucial for effective treatment and preventing irreversible damage.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.1K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K

Related Experiment Videos

Last Updated: Apr 11, 2026

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

2.7K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.1K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K

Area of Science:

  • Neurology
  • Neuroimmunology
  • Neuroscience

Background:

  • Multiple sclerosis (MS) is a leading cause of nontraumatic neurological disability in young adults.
  • MS is characterized by central nervous system (CNS) inflammation, demyelination, and neurodegeneration.
  • Disease progression varies significantly among individuals, with some experiencing rapid disability accumulation, termed aggressive MS.

Purpose of the Study:

  • To highlight the challenges in treating aggressive MS.
  • To emphasize the importance of early identification of patients at risk for aggressive MS.
  • To underscore the need for effective early intervention strategies to prevent irreversible damage and secondary progression.

Main Methods:

  • This abstract discusses the clinical presentation and management challenges of aggressive MS.
  • It reviews the current understanding of disease heterogeneity in MS.
  • The text emphasizes the need for early diagnostic and therapeutic approaches.

Main Results:

  • Aggressive MS is defined by rapid disability progression over a short period.
  • Optimal treatment strategies for aggressive MS are not yet established.
  • Early intervention may prevent irreversible neurological damage and secondary progressive MS.

Conclusions:

  • Early identification and intervention are critical for managing aggressive MS.
  • Effective treatment strategies are needed to mitigate rapid disability progression.
  • Preventing the transition to secondary progressive MS is a key therapeutic goal.